Pathogenic SETD2 mutations have been detected in several cancers, including renal cell carcinomas, breast carcinomas, lung cancers, central nervous system tumors, leukemia [25,26,27,28], and lymphoma in particular MEITL and hepatosplenic T-cell lymphoma [29]. Here, SETD2 is linked to hepatosplenic T-cell lymphoma.